Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62LloFoxP3+CD4+ T cells with limited suppressor activity

European Journal of Immunology

Volumn 41, Issue 5, 2011, Pages 1480-1490

  Goudy, Kevin S ^a   Johnson, Mark C ^a   Garland, Alaina ^a   Li, Chengwen ^a   Samulski, Richard J ^a   Wang, Bo ^a   Tisch, Roland ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Immunoregulation; Tregs; Type 1 diabetes

Indexed keywords

INTERLEUKIN 2; L SELECTIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SECRETION; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; INTERLEUKIN-2; ISLETS OF LANGERHANS; L-SELECTIN; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; PANCREAS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 79955133918     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040890     Document Type: Article

References (51)

1. Bach, J. F., Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 1994. 15: 516-542.
2. Chatenoud, L., Thervet, E., Primo, J. and Bach, J. F., Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 1994. 91: 123-127.
3. Chatenoud, L., Primo, J. and Bach, J. F., CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 1997. 158: 2947-2954.
4. Gregori, S., Giarratana, N., Smiroldo, S., and Adorini, L., Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 2003. 171: 4040-4047.
5. You, S., Belghith, M., Cobbold, S., Alyanakian, M. A., Gouarin, C., Barriot, S., Garcia, C. et al., Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005. 54: 1415-1422.
6. Brusko, T. M., Wasserfall, C. H., Clare-Salzler, M. J., Schatz, D. A. and Atkinson, M. A., Functional defects and the influence of age on the frequency of CD4+CD25+T-cells in type 1 diabetes. Diabetes 2005. 54: 1407-1414.
7. Pop, S. M., Wong, C. P., Culton, D. A., Clarke, S. H. and Tisch, R., Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+regulatory T cells during autoimmune diabetes. J. Exp. Med. 2005. 201: 1333-1346.
8. Ramsdell, F., Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003. 19: 165-168.
9. Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A. and Weiner, H. L., Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994. 265: 1237-1240.
10. Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J. E. and Roncarolo, M. G., A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997. 389: 737-742.
11. Chen, Z., Herman, A. E., Matos, M., Mathis, D. and Benoist, C., Where CD4+CD25+T reg cells impinge on autoimmune diabetes. J. Exp. Med. 2005. 202: 1387-1397.
12. Hori, S., Nomura, T. and Sakaguchi, S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003. 299: 1057-1061.
13. Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E. et al., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001. 27: 20-21.
14. Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S. A., Wilkinson, J. E. et al., Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001. 27: 68-73.
15. Chatila, T. A., Blaeser, F., Ho, N., Lederman, H. M., Voulgaropoulos, C., Helms, C. and Bowcock, A. M., JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 2000. 106: R75-R81.
16. Bluestone, J. A. and Boehmer, H., Regulatory T cells. Semin. Immunol. 2006. 18: 77.
17. Zheng, S. G., Wang, J., Wang, P., Gray, J. D. and Horwitz, D. A., IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+regulatory T cells and for expansion of these cells. J. Immunol. 2007. 178: 2018-2027.
18. Conti, P., Kempuraj, D., Frydas, S., Kandere, K., Boucher, W., Letourneau, R., Madhappan, B. et al., IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol. Lett. 2003. 88: 171-174.
19. Szanya, V., Ermann, J., Taylor, C., Holness, C. and Fathman, C. G., The subpopulation of CD4+CD25+splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 2002. 169: 2461-2465.
20. Ermann, J., Hoffmann, P., Edinger, M., Dutt, S., Blankenberg, F. G., Higgins, J. P., Negrin, R. S. et al., Only the CD62L+subpopulation of CD4+CD25+regulatory T cells protects from lethal acute GVHD. Blood 2005. 105: 2220-2226.
21. Fisson, S., Darrasse-Jeze, G., Litvinova, E., Septier, F., Klatzmann, D., Liblau, R. and Salomon, B. L., Continuous activation of autoreactive CD4+CD25+regulatory T cells in the steady state. J. Exp. Med. 2003. 198: 737-746.
22. Huehn, J., Siegmund, K., Lehmann, J. C., Siewert, C., Haubold, U., Feuerer, M., Debes, G. F. et al., Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+regulatory T cells. J. Exp. Med. 2004. 199: 303-313.
23. Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L. et al., In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004. 199: 1455-1465.
24. Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A. et al., Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008. 28: 687-697.
25. Antony, P. A., Paulos, C. M., Ahmadzadeh, M., Akpinarli, A., Palmer, D. C., Sato, N., Kaiser, A. et al., Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J. Immunol. 2006. 176: 5255-5266.
26. Schoenberger, S. P. and Janssen, E. M., IL-2 gets with the program. Nat. Immunol. 2006. 7: 798-800.
27. Furtado, G. C., Curotto de Lafaille, M. A., Kutchukhidze, N. and Lafaille, J. J., Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 2002. 196: 851-857.
28. Malek, T. R., Yu, A., Vincek, V., Scibelli, P. and Kong, L., CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002. 17: 167-178.
29. Setoguchi, R., Hori, S., Takahashi, T. and Sakaguchi, S., Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005. 201: 723-735.
30. Thornton, A. M., Donovan, E. E., Piccirillo, C. A. and Shevach, E. M., Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+T cell suppressor function. J. Immunol. 2004. 172: 6519-6523.
31. Davidson, T. S., DiPaolo, R. J., Andersson, J. and Shevach, E. M., Cutting edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+T regulatory cells. J. Immunol. 2007. 178: 4022-4026.
32. Maier, L. M., and Wicker, L. S., Genetic susceptibility to type 1 diabetes. Curr. Opin. Immunol. 2005. 17: 601-608.
33. Onengut-Gumuscu, S., and Concannon, P., Recent advances in the immunogenetics of human type 1 diabetes. Curr. Opin. Immunol. 2006. 18: 634-638.
34. King, C., Ilic, A., Koelsch, K. and Sarvetnick, N., Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004. 117: 265-277.
35. Encinas, J. A., Wicker, L. S., Peterson, L. B., Mukasa, A., Teuscher, C., Sobel, R., Weiner, H. L. et al., QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. Nat. Genet. 1999. 21: 158-160.
36. McGuire, H. M., Vogelzang, A., Hill, N., Flodstrom-Tullberg, M., Sprent, J. and King, C., Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc. Natl. Acad. Sci. USA 2009. 106: 19438-19443.
37. Yamanouchi, J., Rainbow, D., Serra, P., Howlett, S., Hunter, K., Garner, V. E., Gonzalez-Munoz, A. et al., Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 2007. 39: 329-337.
38. Sgouroudis, E., Albanese, A. and Piccirillo, C. A., Impact of protective IL-2 allelic variants on CD4+Foxp3+regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J. Immunol. 2008. 181: 6283-6292.
39. Lyons, P. A., Armitage, N., Argentina, F., Denny, P., Hill, N. J., Lord, C. J., Wilusz, M. B. et al., Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res. 2000. 10: 446-453.
40. Sutherland, A. P., Van Belle, T., Wurster, A. L., Suto, A., Michaud, M., Zhang, D., Grusby, M. J. et al., Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009. 58: 1144-1155.
41. Datta, S. and Sarvetnick, N. E., IL-21 limits peripheral lymphocyte numbers through T cell homeostatic mechanisms. PLoS One 2008. 3: e3118.
42. Spolski, R., Kashyap, M., Robinson, C., Yu, Z. and Leonard, W. J., IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 2008. 105: 14028-14033.
43. Peluso, I., Fantini, M. C., Fina, D., Caruso, R., Boirivant, M., MacDonald, T. T., Pallone, F., and Monteleone, G., IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+T lymphocytes. J. Immunol. 2007. 178: 732-739.
44. Clough, L. E., Wang, C. J., Schmidt, E. M., Booth, G., Hou, T. Z., Ryan, G. A., and Walker, L. S. K., Release of regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J. Immunol. 2008. 180:5393-5401.
45. D'Alise, A. M., Auyeung, V., Feuerer, M., Nishio, J., Fontenot, J., Benoist, C. and Mathis, D., The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl. Acad. Sci. USA 2008. 105: 19857-19862.
46. Kamanaka, M., Rainbow, D., Schuster-Gossler, K., Eynon, E. E., Chervonsky, A. V., Wicker, L. S. and Flavell, R. A., Amino acid polymorphisms altering the glycosylation of IL-2 do not protect from type 1 diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 2009. 106: 11236-11240.
47. Malek, T. R., The biology of Interleukin-2. Annu. Rev. Immunol. 2008. 26: 453-479.
48. Hamilton-Williams, E. E., Martinez, X., Clark, J., Howlett, S., Hunter, K. M., Rainbow, D. B., Wen, L. et al., Expression of diabetes-associated genes by dendritic cells and CD4 T cells drives the loss of tolerance in nonobese diabetic mice. J. Immunol. 2009. 183: 1533-1541.
49. Anderson, A. C., Chandwaskar, R., Lee, D. H. and Kuchroo, V. K., Cutting edge: the Idd3 genetic interval determines regulatory T cell function through CD11b+CD11c- APC. J. Immunol. 2008. 181: 7449-7452.
50. Wong, C. P., Stevens, R., Long, B., Li, L., Wang, Y., Wallet, M. A., Goudy, K. S. et al., Identical beta cell-specific CD8(+) T cell clonotypes typically reside in both peripheral blood lymphocyte and pancreatic islets. J. Immunol. 2007. 178: 1388-1395.
51. Xiao, X., Li, J. and Samulski, R. J., Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 1998. 72: 2224-2232.